Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    31-October-2000      
Issue 201 Next Update - 14:00 UTC 08:00 EST    01-November-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Proceed To Article In Today's Vidyya
man on porch
Merck announces positive results of safety and efficacy studies performed on their osteoarthritis drug, Vioxx.

Proceed To Article Fertility Researchers Discover New Gene Essential For Female Fertility
Fertility researchers at the National Institute of Child Health and Human Development (NICHD) have found that a gene in female mice is essential for their egg cells to later develop beyond the two-cell stage after fertilization. This finding could lead to new insights into the causes of unexplained infertility in women. The finding may also provide an important lead for developmental biologists studying how an organism progresses from a single cell to a complex organism. More...

Proceed To Article Scientists Report Advance In Tackling Common Viral Respiratory Disease
Respiratory infections strike millions of people each year and collectively cause more deaths than any single infectious disease. For the first time, scientists have determined the structure of a key protein from a paramyxovirus, a leading cause of respiratory disease in children throughout the world. More...

Proceed To Article First Study Evaluating The Efficacy And Tolerability Of Vioxx, Celecoxib And Acetaminophen For Osteoarthritis Presented
In a new study, Vioxx® 25 mg (rofecoxib), the prescription osteoarthritis medicine developed and marketed by Merck & Co., Inc., reduced osteoarthritis pain at night and at rest to a greater degree than celecoxib 200 mg and acetaminophen 4,000 mg. Results of the study were reported yesterday at the annual meeting of the European League Against Rheumatism, the largest rheumatology conference in Europe. More...

Proceed To Article Renal Safety Profile of Vioxx® Confirmed
In an analysis presented at the European League Against Rheumatism (EULAR), the renal safety profile of Vioxx(R) (rofecoxib) was not statistically different from celecoxib. In a separate analysis, Vioxx had a renal safety profile that is similar to that of certain non-steroidal anti-inflammatory drugs (NSAIDs), Merck & Co., Inc. confirmed today in response to a news release by a competitor. More...

Proceed To Article

Prescribing Information - Vioxx®
Vioxx is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Vioxx is believed to be due to inhibition of prostaglandin synthesis, via inhibition of cyclooxygenase-2 (COX-2). More...

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.